Bio-Techne

Bio-Techne Gross Margin

The Gross Margin of Bio-Techne (TECH) as of Oct 9, 2026 is 65.77 %. In the previous year, Gross Margin was 64.80 % — a change of 1.50% (higher).

Gross Margin

65.77 %

YoY

1.50%

Last updated:

Gross Margin of Bio-Techne is 2026 65.77 % . Gross Margin of Bio-Techne was 2025 64.80 % . It decreases by 1.50% higher compared to the previous year.

Bio-Techne's gross margin stands at 65.8%, down from 68.4% several years earlier.

The Bio-Techne Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
66.31 USD
Jan 1, 2020
65.41 USD
Jan 1, 2021
67.97 USD
Jan 1, 2022
68.42 USD
Jan 1, 2023
67.72 USD
Jan 1, 2024
66.41 USD
Jan 1, 2025
64.80 USD
Jan 1, 2026
65.77 USD
The Bio-Techne Gross Margin history
YEARGross MarginYoY
65.77 %+1.50%
64.80 %-2.43%
66.41 %-1.94%
67.72 %-1.02%
68.42 %+0.66%
67.97 %+3.91%
65.41 %-1.36%
66.31 %-1.33%
67.21 %+1.03%
66.53 %-1.39%
67.46 %-0.71%
67.94 %-3.31%
70.27 %+9,343.58%
0.74 %-0.73%
0.75 %-3.37%
0.78 %-2.74%
0.80 %+0.99%
0.79 %-0.60%
0.79 %+0.42%
0.79 %—
Access this data via the Eulerpool API

Bio-Techne Stock analysis

What does Bio-Techne do? Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Techne stock

Gross Margin of Bio-Techne is 65.77 % in 2026.

Gross Margin of Bio-Techne changed from 64.80 % to 65.77 %, representing a 1.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Bio-Techne since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Bio-Techne with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

Margins — Bio-Techne

All Key Metrics — Bio-Techne